The Alliance for Regenerative Medicine (ARM)'s mission is to advance regenerative medicine by representing, supporting and engaging all stakeholders in the field, including companies, academic research institutions, patient advocacy groups, foundations, health insurers, financial institutions and other organizations.
Based in Washington, D.C., ARM is a global advocacy organization that promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare.
“ For the past several years, The Life Sciences Report (TLSR) has served as a major proponent of the Alliance for Regenerative Medicine (ARM) and our members. Their unique formula for reaching investors, both institutional and retail, via in-depth interviews, has helped educate the investor community and propel growth in the regenerative medicine sector. We feel TLSR's commitment to quality content is a constant consideration in everything they do, and their combination of information and insight is a unique feature not found anywhere else. We value our continued partnership with TLSR, proudly support their activities and greatly appreciate their on-going endorsement of ARM and our members. ”
—Alliance for Regenerative Medicine
Companies
Advanced Cell Technology Inc.
Applied Genetic Technologies Corp.
Athersys Inc.
Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. More
Avita Medical Ltd.
AxoGen Inc.
Baxter International Inc.
Beckman Coulter Inc.
BioLife Solutions Inc.
BioLife Solutions Inc. develops, manufactures and markets hypothermic storage and cryopreservation freeze media products for cells, tissues and organs. More
BioTime Inc.
bluebird bio Inc.
BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. More
Caladrius Biosciences Inc.
Caladrius Biosciences Inc. (formerly NeoStem Inc.) is an international biopharmaceutical company. The company operates in three segments: Cell therapy (United States), regenerative medicine (China) and pharmaceutical manufacturing (China). More
Celgene Corp.
Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is a fully integrated regenerative medicine company that combines cell-therapy-related devices, patented platform technology, and proprietary cell formulations and treatment protocols for the development of commercializable cell therapies. More
Cynata Therapeutics Ltd.
Cynata Therapeutics Ltd. is an Australian stem cell and regenerative medicine company that is developing Cymerus, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison. More
Fate Therapeutics Inc.
Fibrocell Science Inc.
Fisher BioServices Inc.
GenVec Inc.
Harvard Bioscience Inc.
InVivo Therapeutics Holdings Corp.
Johnson & Johnson
Life Technologies Corp.
Medistem Inc.
Mesoblast Ltd.
Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. More
MiMedx Group Inc.
NUO Therapeutics, Inc.
Organovo Holdings Inc.
Osiris Therapeutics Inc.
Pfizer Inc.
Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. is a biotechnology company that is developing off-the-shelf cell therapies for a variety of human diseases. More
Plus Therapeutics Inc.
ReNeuron Group Plc
RepliCel Life Sciences Inc.
RepliCel Life Sciences Inc. is a regenerative medicine company developing autologous cell therapies that treat functional cellular deficits utilizing cells isolated from a patient's own healthy hair follicles. More
Roche Holding AG
Sangamo Therapeutics Inc.
Shire Plc
StemCells Inc.
StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. More
TiGenix NV
Vericel Corp.
Notable Quotes
| "A mine life of ~20 years is a probable outcome for LTH's Bandeira." | ❭ |
| "ABRA's Diablillos is a prime candidate for larger predators' attention." | ❭ |
| "We expect the OIII-Agnico Eagle deal to be approved." | ❭ |
| "TAU's offering will generate gross proceeds of up to $7M." | ❭ |
| "KSM continues making SEA one of the sector's better optionality plays." | ❭ |
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
